Next Article in Journal
Advances in Radiation Oncology for the Treatment of Cervical Cancer
Previous Article in Journal
An Individualized Exercise Intervention for People with Multiple Myeloma—Study Protocol of a Randomized Waitlist-Controlled Trial
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 29
Issue 2
10.3390/curroncol29020078
Review Report
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Conference Report
Peer-Review Record

Report from the Western Canadian Gastrointestinal Consensus Cancer Conference—Management of Total Neoadjuvant Therapy in Rectal Cancer

Curr. Oncol. 2022, 29(2), 924-927; https://doi.org/10.3390/curroncol29020078
by Howard Lim 1,*, Aswin George Abraham 2, Shahid Ahmed 3, Shahida Ahmed 4, Carl J. Brown 5, Bryan Brunet 3, Janine Davies 1, Corinne Doll 6, Dorie-Anna Dueck 3, Vallerie Gordon 4, Kimberly Hagel 7, Pamela Hebbard 4, Christina A. Kim 4, Duc Le 3, Richard Lee-Ying 6, John Paul McGhie 8, Karen Mulder 2, Jason Park 5, Daniel J. Renouf 1, Devin Schellenberg 9, Ralph P. W. Wong 4 and Adnan Zaidi 3add Show full author list remove Hide full author list
Reviewer 1: Anonymous
Curr. Oncol. 2022, 29(2), 924-927; https://doi.org/10.3390/curroncol29020078
Submission received: 9 December 2021 / Revised: 13 January 2022 / Accepted: 24 January 2022 / Published: 8 February 2022
(This article belongs to the Section Gastrointestinal Oncology)

Round 1

Reviewer 1 Report

Rectal cancer care is every evolving with major additions and changes over the last decade, to include local excision, TNT, and Watch and Wait options.  The review of the consensus statement from the virtual educational series highlights the trend to TNT in rectal cancer care.  See comments below:

 

  1. Page 1, MDT rounds should be further described as to the attendees and format.  Highlight the review of pathology, imaging and treatment discussion with the participants that include radiology, pathology, medical oncology, radiation oncology and surgeons.
  2. Page 1, It can be performed should be changed to TNT can be performed.
  3. Page 1, TNT can also be used in N1 disease
  4. Page 2, need to differentiate between pathologic complete response and clinical complete response
  5. Page 2, local excision with or without neoadjuvant therapy, which should be based on the final pathologic specimen
  6. Page 2, with early salvage surgery if recurrent disease.
  7. Page 2, extra space between group and had (in the second to last paragraph)
  8. Page 2, omit the second parentheses after DRE
  9.  Page 2, Patients with...complete or near complete clinical response.  Must clarify if using pathologic clinical response or clinical response
  10. Page 3, first paragraph, change Disease free survival to disease free survival
  11. Page, 3, first paragraph, CT chest, abdomen, and pelvis was performed yearly for years.  Specify how many years
  12. Page 3, GRECCAR2 is a phase III trial...

Author Response

Thank you for your comments - all the edits have been with the exception of below.

Page 2, local excision with or without neoadjuvant therapy, which should be based on the final pathologic specimen

  • Some clarification is needed here - neoadjuvant therapy would be given prior to the final pathologic specimen - so please explain what the final pathologic specimen would change in terms of management.  Is this in regards to further surgery?

Patients with...complete or near complete clinical response.  Must clarify if using pathologic clinical response or clinical response

The statement has clinical response which is different than pathologic response.  Please clarify pathologic clinical response comment.

 

Back to TopTop